Table 2.
Clinically significant immune-related adverse events*.
| All grade | Grade ≥ 3 | |
|---|---|---|
| Dermatologic | 49 (55.7) | 3 (3.4) |
| Pruritis | 24 (27.3) | — |
| Rash | 23 (26.1) | 3 (3.4) |
| Vitiligo | 2 (2.3) | — |
| Musculoskeletal | 12 (13.6) | 2 (2.3) |
| Myalgia | 5 (5.7) | — |
| Myositis | 1 (1.1) | 1 (1.1) |
| Myasthenia gravis | 1 (1.1) | 1 (1.1) |
| Arthralgia | 3 (3.4) | — |
| Arthritis | 2 (2.3) | — |
| Pulmonary | 11 (12.5) | 9 (10.2) |
| Endocrinopathy | 7 (8.0) | — |
| Gastrointestinal | 5 (5.7) | 1 (1.1) |
| Diarrhea | 4 (4.6) | — |
| Enterocolitis | 1 (1.1) | 1 (1.1) |
| Hepatic | 3 (3.4) | 1 (1.1) |
| Dry mouth | 1 (1.1) | — |
| Total | 88 (100.0) | 16 (18.2) |
*All data are presented as number of cases (%).